Inhibitor development against FVIII in previously treated patients with haemophilia A - A retrospective data collection;Inhibitorentwicklung bei FVIII-Präparaten in vorbehandelten Patienten mit Hämophilie A: Eine retrospektive Datenerhebung

Hamostaseologie

Volumn 30, Issue SUPPL.1, 2010, Pages 37-39

  Siegmund, B ^a   Pollmann, H ^a   Richter, H ^a   Orlovic, M ^b   Gottstein, S ^b   Klamroth, R ^b  

^a Inst fur Thromb Hamostaseologie   (Germany)

^b VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

Author keywords

Factor VIII; Haemophilia A; Inhibitor; PTP

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; HEMOPHILIA A; HUMAN; RETROSPECTIVE STUDY; SAFETY;

FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SAFETY;

EID: 79952115363     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 310: 933.
2. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-950.
3. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-988.
4. Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost 2004; 2: 861-862.
5. Lusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost 2004; 2: 863-865.
6. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
7. McMillan CW, Shapiro SS, Whitehurst D et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. Blood 1988; 71: 344-348.
8. Scharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Review article. Haemophilia 2001; 7: 346-348.
9. Gouw SC, van der Bom JG, Auerswald G et al. for the CANAL Study group. Recombinant versus plasma- derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-4697.